Fenwick Represents Synapticure in $25M Series A Funding

Fenwick represented Synapticure, a virtual care company dedicated to improving access and outcomes for patients and caregivers living with Alzheimer’s and related dementias, Parkinson’s, and other neurodegenerative diseases, in its $25 million Series A financing. The round was led by B Capital, with participation from CommonSpirit Health, CVS Health Ventures, RA Capital Management, Nexus NeuroTech Ventures, Google Ventures, Optum Ventures, and Rock Health Capital.

Synapticure will use the funds to expand partnerships with leading healthcare providers and payers, invest in its innovative and proprietary technology platform, fast-track clinical research and expand patient access, and scale its national medical group. More information can be obtained from the company announcement.

The Fenwick transaction team was led by corporate partners Michael Esquivel and Sarah Chambless and included associates David Heckman, Sloka Tankala, and Santino Labate.